CCM
GYRE icon

CAAS Capital Management’s Gyre Therapeutics GYRE Stock Holding History

CAAS Capital Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-20,769
Closed -$670K – 863
2020
Q3 		$670K Sell
20,769
-26,900
-56% -$1.05M 0.02% 372
2020
Q2 		$2.1M Buy
+47,669
New +$2.24M 0.07% 203

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

CAAS Capital Management's GYRE Position: Q4 2020 in Review

CAAS Capital Management sold out of Gyre Therapeutics (GYRE) in Q4 2020, closing a stake of 20,769 shares — an estimated $670K sold.

CAAS Capital Management first reported a position in GYRE in Q2 2020 and held it in 2 quarters. The position peaked at $2.1M in Q2 2020. 80 funds tracked by Wall St. Rank hold GYRE as of Q4 2020.

  • CAAS Capital Management reported no remaining Gyre Therapeutics position as of Q4 2020 after selling out during the quarter.
  • CAAS Capital Management sold 20,769 Gyre Therapeutics shares in Q4 2020, an estimated $670K.
  • CAAS Capital Management first reported a position in Gyre Therapeutics in Q2 2020 and held it in 2 quarters.
  • CAAS Capital Management's Gyre Therapeutics position peaked at $2.1M in Q2 2020.
  • 80 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2020.

Based on CAAS Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.